Drug intelligence / Profile preview

milfasartan

Development stage: Unknown
Lead developer: Knoll
Modality: Small Molecules
Administration: Oral

Overview

Milfasartan (美阿沙坦钾) is a small molecule angiotensin II receptor blocker (ARB) developed by Beijing Foyou Pharmaceutical for the treatment of hypertension. It acts as a selective antagonist of the angiotensin II type 1 (AT1) receptor, thereby inhibiting the vasopressor and aldosterone-secreting effects of angiotensin II. By blocking these pathways, milfasartan promotes vasodilation and reduces peripheral vascular resistance, leading to a decrease in blood pressure. The drug is approved in China for the management of essential hypertension and is typically administered as a potassium salt formulation.

Brand names: 美阿沙坦钾片
Other names: 美阿沙坦钾Azilsartan potassiumMilfasartan Tablets

Targets

AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on milfasartan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on milfasartan.

Explore the full profile